Skip to main content

Table 2 Participant and data characteristics

From: Patient and health practitioner views and experiences of a cancer trial before and during COVID-19: qualitative study

Patient interviews

N = 26

 Age

 

  Median years (range)

62 (42–75)

 Sex

 

  Females/males

14/12

 Index of multiple deprivation decilea

 

  Most deprived (1–3)

4

  Average deprivation (4–7)

11

  Least deprived (8–10)

8

 Format of interview

 

  Telephone

26

 Duration of interview

 

  Median minutes (range)

61 (40–84)

 PETReA trial participation status

 

  Consent (v declined)

25 (v 1)

 PET-CT response to induction and trial arm allocationb

n = 25

  Complete metabolic response (CR)

 

   No further treatment

9

   Maintenance

8

  Partial response (PR)

 

   Maintenance

4

   Maintenance plus Lenalidomide

4

 No. of participating UK sites

12

Practitioner interviews

N = 15

 Practitioner’s role

 

  Haematologist oncologist

10

  Research nurses/clinical trial practitionersc

5

 Format of interview

 

  Telephone

11

  Face-to-face

3

  Video call

1

 Duration of interview

 

  Median minutes (range)

62 (32–81)

 No. of participating UK sites

12

Total interviews

41

 No. of participating UK sites

16

  1. aThe Index of Multiple Deprivation (IMD) deciles were available only for those patients living in mainland England (n=23/26). IMD ranks every small area in England from 1 (most deprived area) to 32,844 (least deprived area). The deciles are derived from the ranks and we divided these into most deprived (1–3), average deprivation (4–7), and least deprived (8–10). bTrial participants only. cClinical trials practitioner is a reasonably new role in the NHS, which entails trial recruitment, education, support and monitoring of the patient entering a clinical trial